会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 57. 发明公开
    • 피부질환 치료에 유용한 은행잎 추출물
    • GINKGO BILOBA提取物用于治疗皮肤病
    • KR1020070071350A
    • 2007-07-04
    • KR1020050134704
    • 2005-12-30
    • 에스케이케미칼주식회사
    • 곽의종조용백한창균이은주김주현윤세준이순근
    • A61K36/16A61P17/00
    • An extract of Ginkgo biloba L. for the treatment of dermatological disease is provided to inhibit epidermal hyperproliferation caused by abnormal expression of genes associated with epidermal differentiation and epidermal proliferation and reduce side effects. A composition for the treatment of dermatological disease including psoriasis comprises the extract of Ginkgo biloba L. which contains biflavonoid and is prepared by extracting leaves of Ginkgo biloba L. with water or alcohol, fractionating the extract with lower alcohol or nonpolar solvent, concentrating the fraction, washing the concentrated fraction with normal hexane, and filtering and drying the extract under vacuum. The daily dosage of the Ginkgo biloba extract is 0.1-10 mg/kg; and the composition is formulated as powder, granule, capsule or injection.
    • 提供银杏叶提取物用于治疗皮肤病,用于抑制与表皮分化和表皮增生相关基因异常表达引起的表皮过度增殖,并减少副作用。 用于治疗包括银屑病在内的皮肤病的组合物包含含有双黄酮的银杏提取物,并通过用水或醇提取银杏叶的叶子,用低级醇或非极性溶剂对提取物进行分级,浓缩该级分 用正己烷洗涤浓缩级分,真空过滤干燥提取物。 银杏提取物的日剂量为0.1-10mg / kg; 并将组合物配制成粉末,颗粒,胶囊或注射剂。
    • 58. 发明公开
    • 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
    • 新型吡啶衍生物,其制备方法和含有它们的药物组合物
    • KR1020070066519A
    • 2007-06-27
    • KR1020050127801
    • 2005-12-22
    • 에스케이케미칼주식회사
    • 김형욱류제호정재윤김주현전선덕이해인김은정김지홍노은정조용백곽의종
    • C07D491/052
    • A novel pyridine derivative is provided to inhibit the formation of cytokines involving with the inflammation reaction and specifically have excellent inhibition activity against TNF-alpha, interleukin-1, interleukin-6, interferone-gamma, and PEG3 formation, thereby showing strong effect on inflammation-related diseases, immuno-related diseases, chronic inflammatory diseases and analgesic. The pyridine derivative is represented by the formula(1), in which each R1, R2, R3, R4, R5, R6 an R7 is independently H, halo, cyano, nitro, acyl, hydroxy, amino, C1-6 lower alkyl, C2-6 lower alkenyl, C1-6 lower alkoxy, C1-6 alkylthio, C1-6 alkylamino, C4-9 cycloalkylamino, C4-9 heterocycloalkylamino, C1-10 aralkylamino, arylamino, acylamino, acyloxy, C1-6 alkylsulfinyl, C1-6 alkylsulfonly, C1-6 alkylsulfonylamino, arylsulfinyl, arylsulfonyl, arylsulfonylamino, aryl, heteroaryl, C1-10 arylalkyl, C1-10 heteroaralkyl, aryloxy, or heteroaryloxy, or two of R1-R7 together with a substituent adjacent to each other form a pentagonal ring, a hexagonal ring or a heptagonal ring, X is O or S, and Y is O or NR8(in which R8 is H, C1-6 lower alkyl, acyl, aryl, heteroaryl, C1-10 aralkyl, or C1-10 heteroaralkyl, or R8 and R6 or R7 together with an adjacent substituent form a pentagonal ring, a hexagonal ring or a heptagonal ring). The method comprises the steps of: (a) reacting a compound represented by the formula(2) with an R6 containing alkyl ester compound in the presence of a base to obtain a compound represented by the formula(3); (b) reacting the compound of the formula(2) with a reducing agent or an R7 containing metal reagent at a temperature of 0 to room temperature so as to obtain an alcohol compound represented by the formula(4); and (c) cyclizing the alcohol compound to obtain a compound of the formula(1), in which each of the R1 to R7 is the same as defined above, and each X and Y is O.
    • 提供了一种新型的吡啶衍生物,用于抑制与炎症反应相关的细胞因子的形成,具体具有对TNF-α,白细胞介素-1,白细胞介素-6,干扰素-γ和PEG3形成的优异抑制活性,从而显示出对炎症的强烈作用 相关疾病,免疫相关疾病,慢性炎性疾病和镇痛药。 吡啶衍生物由式(1)表示,其中每个R 1,R 2,R 3,R 4,R 5,R 6和R 7独立地为H,卤素,氰基,硝基,酰基,羟基,氨基,C 1-6低级烷基, C 2-6低级烯基,C 1-6低级烷氧基,C 1-6烷硫基,C 1-6烷基氨基,C 4-9环烷基氨基,C 4-9杂环烷基氨基,C 1-10芳烷基氨基,芳基氨基,酰氨基,酰氧基,C 1-6烷基亚磺酰基, C 1-6烷基磺酰基氨基,芳基亚磺酰基,芳基磺酰基,芳基磺酰基氨基,芳基,杂芳基,C 1-10芳基烷基,C 1-10杂芳烷基,芳氧基或杂芳氧基,或两个R 1 -R 7与彼此相邻的取代基形成五边形 环,六方环或七角环,X为O或S,Y为O或NR8(其中R8为H,C1-6低级烷基,酰基,芳基,杂芳基,C1-10芳烷基或C1-10 杂芳烷基,或R 8和R 6或R 7与相邻取代基一起形成五角环,六方环或七角环)。 该方法包括以下步骤:(a)在碱的存在下使由式(2)表示的化合物与含R6的烷基酯化合物反应,得到式(3)表示的化合物; (b)在0至室温的温度下使式(2)的化合物与还原剂或含R7的金属试剂反应,得到由式(4)表示的醇化合物; 和(c)使醇化合物环化,得到式(1)化合物,其中R 1至R 7各自与上述定义相同,且每个X和Y均为O.